Trevi Therapeutics Inc (NASDAQ:TRVI) shares, rose in value on Thursday, March 27, with the stock price up by 0.85% to the previous day’s close as strong demand from buyers drove the stock to $6.53.
Actively observing the price movement in the last trading, the stock closed the session at $6.47, falling within a range of $6.37 and $6.56. The value of beta (5-year monthly) was 0.91. Referring to stock’s 52-week performance, its high was $7.39, and the low was $2.30. On the whole, TRVI has fluctuated by 44.68% over the past month.
With the market capitalization of Trevi Therapeutics Inc currently standing at about $630.85 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-17.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TRVI’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of TRVI currently trading nearly 11.63% and 35.76% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 67.07, while the 7-day volatility ratio is showing 4.60% which for the 30-day chart, stands at 8.17%. Furthermore, Trevi Therapeutics Inc (TRVI)’s beta value is 0.44, and its average true range (ATR) is 0.43.
A comparison of Trevi Therapeutics Inc (TRVI) with its peers suggests the former has fared considerably weaker in the market. TRVI showed an intraday change of 0.85% in last session, and over the past year, it grew by 94.78%%.
Data on historical trading for Trevi Therapeutics Inc (NASDAQ:TRVI) indicates that the trading volumes over the past 10 days have averaged 1.74 and over the past 3 months, they’ve averaged 1.92 million. According to company’s latest data on outstanding shares, there are 93.60 million shares outstanding.
Nearly 40.90% of Trevi Therapeutics Inc’s shares belong to company insiders and institutional investors own 45.66% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.68 million shares as on 2025-03-14, resulting in a short ratio of 1.11. According to the data, the short interest in Trevi Therapeutics Inc (TRVI) stood at 675.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 4.33 million. The stock has risen by 58.37% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TRVI stock heading into the next quarter.
